Non-Cystic Fibrosis Bronchiectasis Market to Witness Growth During ... - Digital Journal

PRESS RELEASE

Published May 9, 2023

Las Vegas, Nevada, United States, DelveInsight's "Non-cystic Fibrosis Bronchiectasis – Market Insights, Epidemiology and Market Forecast – 2032" report delivers an in-depth understanding of the Non-cystic Fibrosis Bronchiectasis, historical and forecasted epidemiology as well as the Non-cystic Fibrosis Bronchiectasis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.

 Non-Cystic Fibrosis Bronchiectasis Overview

Non‐Cystic Fibrosis Bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production, and recurrent pulmonary infections. Bronchiectasis may result from a number of infectious and acquired causes, including measles, pneumonia, tuberculosis, immune system problems, as well as the genetic disorder cystic fibrosis. Cystic fibrosis eventually results in severe bronchiectasis in nearly all cases. The cause in 10–50% of those without cystic fibrosis is unknown. 

The disease mechanism is a breakdown of the airways due to an excessive inflammatory response. Involved airways (bronchi) become enlarged and thus less able to clear secretions. These secretions increase the amount of bacteria in the lungs, resulting in airway blockage and further breakdown of the airways.

 Non-Cystic Fibrosis Bronchiectasis Epidemiological Insights

• The total number of diagnosed prevalent cases of Non-cystic Fibrosis Bronchiectasis in the United States was around 368,286 cases in 2022.
• China contributed to the largest diagnosed prevalent population of Non-cystic Fibrosis Bronchiectasis, acquiring ~85.64% of the 7MM + China in 2022. Whereas the US, EU4, and the UK, and Japan accounted for around 3.92%, 5.24%, and 5.20% of the total population share, respectively, in 2022.
• In the US, females diagnosed with Non-cystic Fibrosis Bronchiectasis are higher in number than males. In 2022, cases of Non-cystic Fibrosis Bronchiectasis among females were approximately 242,332, while among the male population, there were approximately 125,954 NCFB cases. These numbers are expected to rise during the study period.
• According to DelveInsight estimates, in EU4 and the UK, the prevalence of moderate cases of Non-cystic Fibrosis Bronchiectasis is the highest, followed by mild Non-cystic Fibrosis Bronchiectasis and severe Non-cystic Fibrosis Bronchiectasis cases. In 2022, there were approximately 196,848 moderate, 152,557 mild, and 142,715 severe Non-cystic Fibrosis Bronchiectasis cases in EU4 and the UK, projected to increase during the forecast period.
• In 2022, 97,810, 4,891, 7,336, 6,113, 206,624, and 166,278 Non-cystic Fibrosis Bronchiectasis cases were associated with post-infection, COPD, immunodeficiency, asthma, others, and unknown/Idiopathic etiologies in Japan.
• In 2022, there were 2,172,915 NCFB cases colonized with P. aeruginosa in China, followed by 1,851,002 Non-cystic Fibrosis Bronchiectasis cases colonized with H. influenza, 1,770,524 Non-cystic Fibrosis Bronchiectasis cases with no pathogen growth, 1,609,567 NCFB cases colonized with other pathogens, and 643,827 Non-cystic Fibrosis Bronchiectasis cases colonized with S. pneumonia.

Leading Companies Working in the Non-Cystic Fibrosis Bronchiectasis Market

• Insmed Incorporated
• AstraZeneca
• Zambon
• CSL Behring
• Chiesi Farmaceutici

And many others 

Promising Therapies in the Non-Cystic Fibrosis Bronchiectasis 

• Ciprofloxacin
• Benralizumab
• BI1323495
• Brensocatib

And many others 

Learn more about the Non-Cystic Fibrosis Bronchiectasis key companies and emerging therapies @  Non-Cystic Fibrosis Bronchiectasis Therapeutics Market Analysis

Scope of the Non-Cystic Fibrosis Bronchiectasis Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, Japan]

Key Non-Cystic Fibrosis Bronchiectasis Companies: Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Boehringer Ingelheim and many others.

Key  Non-Cystic Fibrosis Bronchiectasis Therapies: Ciprofloxacin, Benralizumab, Brensocatib, BI 1323495, HSK31858, TIP, and many others 

Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis   current marketed and emerging therapies

 Non-Cystic Fibrosis Bronchiectasis Market Dynamics:  Non-Cystic Fibrosis Bronchiectasis   market drivers and barriers 

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Unmet Needs, KOL's views, Analyst's views, Non-Cystic Fibrosis Bronchiectasis Market Access and Reimbursement

Table of Contents

1. Non-Cystic Fibrosis Bronchiectasis Market Key Insights
2. Non-Cystic Fibrosis Bronchiectasis Market Report Introduction
3. Non-Cystic Fibrosis Bronchiectasis Market Overview at a Glance
4. Non-Cystic Fibrosis Bronchiectasis Market Executive Summary
5. Disease Background and Overview
6. Non-Cystic Fibrosis Bronchiectasis Treatment and Management
7. Non-Cystic Fibrosis Bronchiectasis Epidemiology and Patient Population
8. Patient Journey
9. Non-Cystic Fibrosis Bronchiectasis Emerging Drugs
10. 7MM  Non-Cystic Fibrosis Bronchiectasis Market Analysis
11. Non-Cystic Fibrosis Bronchiectasis Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Non-Cystic Fibrosis Bronchiectasis Market Drivers
15. Non-Cystic Fibrosis Bronchiectasis Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Download the sample pages @ Non-Cystic Fibrosis Bronchiectasis Market Outlook

Trending Reports 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Contact Us

Adya Kaul

+1(919)321-6187

[email protected]

www.delveinsight.com

Newsmantraa

Adblock test (Why?)